Avalyn Pharma Adds Blueprint Medicines Veteran Kate Haviland to Board
Event summary
- Kate Haviland, former CEO of Blueprint Medicines, joins Avalyn Pharma's board on March 5, 2026.
- Haviland led Blueprint Medicines through its $9.5 billion acquisition by Sanofi in 2025.
- Avalyn is advancing inhaled therapies for pulmonary fibrosis with Phase 2 trials underway.
- Haviland brings commercialization expertise as Avalyn prepares for late-stage development.
The big picture
Avalyn Pharma is strengthening its governance with a seasoned biopharmaceutical executive as it prepares to transition from clinical-stage to commercialization. The appointment of Kate Haviland, who orchestrated Blueprint Medicines' successful exit to Sanofi, signals Avalyn's focus on scaling its inhaled antifibrotic portfolio. This move comes amid growing interest in targeted respiratory therapies and reflects the industry's shift toward specialized treatments for rare pulmonary diseases.
What we're watching
- Commercialization Timing
- How quickly Avalyn can leverage Haviland's experience to accelerate its commercial strategy as it moves toward late-stage development.
- Pipeline Progress
- The pace at which Avalyn advances its Phase 2 trials for AP01 and AP02, particularly in pulmonary fibrosis indications.
- Strategic Partnerships
- Whether Haviland's connections can facilitate new collaborations or business development opportunities for Avalyn.